Baseline demographic, somatometric and clinical data of the study population
| Whole cohort (N=304) | Nephrosclerosis (N=220; 72.3%) | Other kidney diseases (N=84; 27.7%) | p value | |
| Age (years) | 69±4 | 70±4 | 68±3 | 0.16 |
| Male sex, n (%) | 194 (64.1) | 139 (63.2) | 55 (65.5) | 0.70 |
| BMI (kg/m2) | 27.5±4.1 | 28.1±5.2 | 27.1±4.3 | 0.07 |
| Systolic blood pressure (mm Hg) | 133±18 | 139±14 | 132±27 | 0.06 |
| Diastolic blood pressure (mm Hg) | 75±11 | 76±11 | 73±12 | 0.23 |
| Diabetes, n (%) | 163 (53.6) | 138 (62.7) | 25 (29.7) | <0.001 |
| Total cholesterol (mg/dL) | 172±46 | 159±52 | 181±49 | 0.004 |
| HDL cholesterol (mg/dL) | 51±24 | 50±11 | 51±28 | 0.21 |
| LDL cholesterol (mg/dL) | 109±42 | 103.3±40.9 | 119.5±41.1 | 0.03 |
| Hemoglobin (g/dL) | 13.2±1.9 | 13.1±1.8 | 13.2±1.4 | 0.56 |
| eGFR (mL/min/1.73 m2) | 44.2±19.6 | 41.0±17.1 | 70.8±28.2 | <0.001 |
| Creatinine (mg/dL) | 1.99±0.90 | 2.08±0.68 | 1.62±0.83 | 0.01 |
| Glycemia (mg/dL) | 117±17 | 126±19 | 109±23 | 0.04 |
| Proteinuria (g/24 hours) | 0.4 [0.1–0.9) | 0.2 [0.1–0.8) | 0.6 [0.2–1.5) | <0.001 |
| Urinary sodium (mg/24 hours) | 133±35 | 136±31 | 130±19 | 0.08 |
| Vitamin D (mcg/dL) | 24.3±15.7 | 24.7±11.1 | 24.1±12.0 | 0.31 |
| Statins use, n (%) | 127 (41.7) | 105 (48.6) | 27 (32.1) | 0.01 |
| ESAs use, n (%) | 37 (12.1) | 28 (12.7) | 9 (10.7) | 0.63 |
| Anti-hypertensive drugs, n (%) | ||||
| Diuretics | 92 (30.2) | 70 (31.8) | 22 (26.1) | 0.66 |
| Beta blockers | 45 (14.8) | 35 (15.9) | 10 (11.9) | 0.37 |
| ARBs | 176 (57.9) | 111 (50.4) | 65 (76.4) | <0.001 |
| ACEi | 255 (83.8) | 175 (79.5) | 80 (95.2) | 0.006 |
| CCBs | 77 (25.3) | 69 (31.3) | 8 (9.5) | <0.001 |
| History of CV disease, n (%) | ||||
| TIA/Stroke | 30 (10) | 29 (13.1) | 1 (1.2) | <0.001 |
| Peripheral vascular disease | 45 (14.8) | 43 (19.5) | 2 (2.3) | <0.001 |
| Ischemic heart disease | 31 (10.2) | 28 (12.7) | 3 (3.5) | 0.02 |
ACEi, angiotensin converting enzyme-inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; CCBs, calcium channel blockers; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESAs, erythropoietin-stimulating agents; HDL, high density lipoproteins; LDL, low density lipoproteins; TIA, transient ischemic attack.